ERA

Download the full-sized PDF of Effects of Inflammation and the Severity of Disease on the Action and Disposition of DrugsDownload the full-sized PDF

Analytics

Share

Permanent link (DOI): https://doi.org/10.7939/R3901ZP12

Download

Export to: EndNote  |  Zotero  |  Mendeley

Communities

This file is in the following communities:

Graduate Studies and Research, Faculty of

Collections

This file is in the following collections:

Theses and Dissertations

Effects of Inflammation and the Severity of Disease on the Action and Disposition of Drugs Open Access

Descriptions

Other title
Subject/Keyword
pharmacodynamic
inflammation
disease severity
pharmacokinetic
Type of item
Thesis
Degree grantor
University of Alberta
Author or creator
Sanaee,Forughalsadat
Supervisor and department
Jamali, Fakhreddin ( Pharmacy and Pharmaceutical Science)
Examining committee member and department
Lavasanifar, Afsaneh ( Pharmacy and Pharmaceutical Science)
Shulz, Richard (Medicine)
Ndisang, Joseph (Department of Physiology,University of Saschatchewan)
Brocks, Dion ( Pharmacy and Pharmaceutical Science)
Siraki, Arno ( Pharmacy and Pharmaceutical Science)
Department
Faculty of Pharmacy and Pharmaceutical Sciences
Specialization
Pharmaceutical Sciences
Date accepted
2014-04-01T11:36:33Z
Graduation date
2014-06
Degree
Doctor of Philosophy
Degree level
Doctoral
Abstract
Inflammation is involved in the pathogenesis of some cardiovascular diseases and contributes to the observed increased overall mortality rate. It also influences the action and disposition of drugs including some of the cardiovascular agents that are commonly used by patients with inflammatory conditions. This may result in reduced response to pharmacotherapy. Previous studies have demonstrated that inflammatory conditions such as rheumatoid arthritis, old age and obesity result in altered response to verapamil as measured by the PR prolongation despite increased plasma drug concentration. Interestingly, the action and disposition of verapamil are restored in patients, whose rheumatoid arthritis is in remission, pointing to the possibility that the degree of disease severity may have a role in the above observation. Both the reduced clearance, hence, increased plasma drug concentration and diminished pharmacological response caused by inflammatory conditions have been attributed to down-regulations of target proteins, i.e., drug metabolizing enzymes and receptors, respectively. As our first objective, we investigated the effect of disease severity on the pharmacokinetic and pharmacodynamics of verapamil, a well-studied representative of the calcium channel blockers. As a model of inflammation, we chose Crohn’s disease. We observed that increased disease severity decreased response to the drug while elevating its plasma concentration. As our second objective, we studied the action and disposition of nebivolol in rat adjuvant arthritis. Nebivolol is a third generation β-blocker and is thought to be exclusively metabolized in the liver. It is administered as a racemate of equal ratios of the D- (S,R,R,R) and the L- (R,S,S,S) isomers. It has some unique mechanisms of action including a high selectivity for β1 and β3-adrenoceptors. Nebivolol has the ability to release nitric oxide from the cardiovascular endothelium and possesses antioxidant properties which can increase the level of NO by reducing its oxidative inactivation. These benefits suggest nebivolol as the drug of choice in patients with cardiovascular complications when inflammatory conditions exist. As our third objective, we investigated the pharmacokinetics of nebivolol with the aim of finding whether its intestinal metabolism contributes to its first-pass metabolism in the rat. We also investigated the stereospecific pharmacokinetics of nebivolol to determine factors which cause stereoselectivity in its disposition. Our results revealed that the pharmacological response to nebivolol remained unchanged in the presence of inflammation and the gut rather than liver is responsible for drug’s first pass metabolism. The drug’s pharmacokinetic profile is stereoselective due to its stereoselective binding to plasma proteins. This study revealed that neither the pharmacokinetics nor pharmacodynamics of nebivolol are influenced by inflammation, making it unique among the thus far investigated β-blockers such as propranolol and sotalol.
Language
English
DOI
doi:10.7939/R3901ZP12
Rights
Permission is hereby granted to the University of Alberta Libraries to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific research purposes only. Where the thesis is converted to, or otherwise made available in digital form, the University of Alberta will advise potential users of the thesis of these terms. The author reserves all other publication and other rights in association with the copyright in the thesis and, except as herein before provided, neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatsoever without the author's prior written permission.
Citation for previous publication

File Details

Date Uploaded
Date Modified
2014-06-15T07:02:00.103+00:00
Audit Status
Audits have not yet been run on this file.
Characterization
File format: pdf (Portable Document Format)
Mime type: application/pdf
File size: 1790186
Last modified: 2015:10:12 20:01:05-06:00
Filename: Sanaee_Forughalsadat_Spring 2014.pdf
Original checksum: bbd1b7c680fade5ef29a14f6ae2904a2
Well formed: true
Valid: true
File title: {{}}
File author: Forugh
Page count: 195
File language: en-CA
Activity of users you follow
User Activity Date